TY - JOUR AU - Joshi, Samir AU - Telang, Rahul AU - Tambe, Muralidhar AU - Havaldar, Rajesh AU - Sane, Manasi AU - Shaikh, Afshan AU - Roy, Cherry AU - Yathati, Kireet AU - Sonawale, Sanjaykumar AU - Borkar, Rupalee AU - Magar, Rahul AU - Bhitkar, Harshal AU - Shitole, Satish AU - Nakate, Leena AU - Kudrimoti, Jyoti AU - Mave, Vidya T1 - Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India T2 - Emerging Infectious Disease journal PY - 2022 VL - 28 IS - 1 SP - 1 SN - 1080-6059 AB - We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confirmed rhino-sino-orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis. KW - COVID-19 KW - SARS-CoV-2 KW - coronavirus disease 2019 KW - severe acute respiratory syndrome coronavirus 2 KW - viruses KW - respiratory infections KW - zoonoses KW - invasive mucormycosis KW - fungal infections KW - fungi KW - rhino-sino-orbital mucormycosis KW - India DO - 10.3201/eid2801.211636 UR - https://wwwnc.cdc.gov/eid/article/28/1/21-1636_article ER - End of Reference